摘要
在改善生存和响应率研究中,五个抗VEGF / VEGFR制剂用于治疗转移性肾细胞癌(mRCC)没有显著增加患者的生存。这个分析的目的是执行一个meta-分析的研究来探讨其对总生存期(OS)的影响。MEDLINE / PubMed和Cochrane图书馆搜索随机III期试验进行比较,anti-VEGF / VEGFR作为mRCC前期治疗与空白进行对照。搜索仅限于三期试验,数据提取是根据PRISMA进行分析。五个随机III期试验包括共有3469名患者,其中1801人受到anti-VEGF / VEGFR和1668人得到安慰剂或interferon-α治疗。在整个样本中,降低死亡的风险为13%(HR:0.87;95% CI;0.80 - 0.95;P = 0.002)。当患者分为基于使用VEGFR或anti-VEGF单克隆抗体,死亡的风险分别降低为13%和12%。如果只考虑treatmentnaive病人我们可以确认显著减少12%的死亡风险(HR = 0.88;95%可信区间,0.79 - 0.97;P = 0.010)。我们的分析结果报道了VEGF / VEGFR 通路抑制mRCC能够积极得提高总生存率。
关键词: 贝伐单抗,mRCC
Current Drug Targets
Title:Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis
Volume: 16 Issue: 2
Author(s): Roberto Iacovelli, Cora N. Sternberg, Camillo Porta, Elena Verzoni, Filippo de Braud, Bernard Escudier and Giuseppe Procopio
Affiliation:
关键词: 贝伐单抗,mRCC
摘要: Despite the improvement in progression-free survival and response rates, none of the five anti- VEGF/VEGFR agents used for treatment of metastatic renal cell carcinoma (mRCC) reported a significant increase in patients’ survival. This analysis aims to investigate their effect on overall survival (OS), performing a meta-analysis of the available studies. MEDLINE/PubMed and the Cochrane Library were searched for randomised phase III trials that compared anti-VEGF/VEGFR agents with controls as upfront treatment for mRCC. The search was restricted to phase III trials, and data extraction was conducted according to the PRISMA statement. Five randomised phase III trials were included for a total of 3,469 patients; among these, 1,801 received anti-VEGF/VEGFR agents and 1,668 were treated with a placebo or interferon-α. In the overall population, the reduction in the risk of death was 13% (HR: 0.87; 95%CI, 0.80 – 0.95; p=0.002). When patients were divided based on use of VEGFR agents or an anti-VEGF monoclonal antibody, the reduction in the risk of death was 13% and 12%, respectively. If only treatmentnaïve patients are considered, we can confirm a significant reduction of 12% (HR=0.88; 95%CI, 0.79 – 0.97; p=0.010) in the risk of death. Our analysis reports a positive improvement of OS with the inhibition of the VEGF/VEGFR pathway in mRCC.
Export Options
About this article
Cite this article as:
Roberto Iacovelli, Cora N. Sternberg, Camillo Porta, Elena Verzoni, Filippo de Braud, Bernard Escudier and Giuseppe Procopio , Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450115666141120120145
DOI https://dx.doi.org/10.2174/1389450115666141120120145 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Therapies in the Treatment of Renal Cell Carcinoma
Current Medicinal Chemistry Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry Ethnomedicinal Survey of Indigenous Flora for the Management of Cancer in South-Western, Nigeria
Current Traditional Medicine Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Advances in Methods for Therapeutic Peptide Discovery, Design and Development
Current Pharmaceutical Biotechnology Oncogenomics
Current Drug Metabolism Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Protein Kinase Homology Models: Recent Developments and Results
Current Medicinal Chemistry Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Eupatilin Inhibits the Proliferation and Migration of Prostate Cancer Cells through Modulation of PTEN and NF-κB Signaling
Anti-Cancer Agents in Medicinal Chemistry Approaches Towards the Synthesis of Cephalostatins, Ritterazines and Saponins from Ornithogalum saundersiae - New Natural Products With Cytostatic Activity
Current Organic Chemistry Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Subject Index Volume 2
Medicinal Chemistry Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Recent Advances in Structural Studies of the Carbonic Anhydrase Family: The Crystal Structure of Human CA IX and CA XIII
Current Pharmaceutical Design Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
Current Cancer Drug Targets Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry VEGF/VEGFR2 Autocrine Signaling Stimulates Metastasis in Prostate Cancer Cells
Current Angiogenesis (Discontinued)